COMP <GO>
ARWR vs PRAX // FORWARD P/E MULTIPLE
Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. Praxis Precision Medicines Inc. (NASDAQ) • 15-METRIC TALLY: ARWR 7
— PRAX 2
▲ FORWARD P/E MULTIPLE LEADER: ARWR
LAST: $60.49 (+0.47%) • MKT CAP: $8.54B
forward-pe
18.0x
LAST: $288.62 (+1.10%) • MKT CAP: $8.06B
forward-pe
33.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. PRAX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARWR | PRAX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | -35.00% | +46.10 | ARWR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.8x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.84% | -3.09% | +4.93 | ARWR | /fcf-yield <GO> |
| Operating Margin | 11.90% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -0.20% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 8.80% | +171.20 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 26.00 | -19.40 | PRAX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | ARWR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.3 | 56.3 | -13.00 | PRAX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.91 | +0.05 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 18.0x | 33.0x | -15.00 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.54B | $8.06B | $486.2M | ARWR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARWR REV | PRAX REV | ARWR GROSS % | PRAX GROSS % | ARWR FCF | PRAX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | $0 | — | — | $156.9M | -$249.1M |
| FY 2024 | $3.6M | $8.6M | — | — | -$604.3M | -$131.8M |
| FY 2023 | $240.7M | $2.4M | — | — | -$164.7M | -$111.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
PRAX // BETA 0.91